Pharmacogenomic Profile for Evaluating the Metabolization and Activation of Each Therapeutic Agent
What is ChemoSNip?
ChemoSNiP includes the study of SNPs of genes that are included in the metabolism / detoxification of cytostatic drugs or target therapies that are used as cancer therapy.
ingle nucleotide polymorphisms (SNPs) are sequences of DNA variations that may affect how humans develop the disease or respond to chemicals, drugs, and other agents.
Use of the Exam
This test focuses on the efficacy of therapeutic agents against a cancer of an individual patient. ChemoSNiP provides information on the ability of each individual to metabolize and activate each therapeutic agent in its effective form at a normal rate. This test includes all therapeutic agents with anticancer activity (cytostatics).
Benefits of SNP Analysis:
Prediction of drug activation and deactivation
Relation between the SNP and a clinical condition /li>
Prediction of disease development (cardiovascular disease DM-II, etc.) /li>
Preference for response to specific categories of substances/li>
Type of CANCER
All Types of Cancer
"Except for the Cabeca and Central Nervous System"
Type of SAMPLE
Peripheral Blood Normal (20 to 30ml)
RESULT Time
10 to 14 working days
Kit COLLECTION
RGCC provides the necessary collectio13
n kit with detailed instructions for sample collection and logistics, upon request
